Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland.

van Engen, Anke; Casamayor, Montserrat; Loftus, Fidelma; Coen, Martin; Garnham, Andy; Watt, Maureen; Lacey, Larry

van Engen, Anke; Casamayor, Montserrat; Loftus, Fidelma; Coen, Martin; Garnham, Andy; Watt, Maureen; Lacey, Larry.

Afiliação

van Engen A; Quintiles, Hoofddorp, The Netherlands.
Casamayor M; Quintiles, Barcelona, Spain.
Loftus F; Astellas Pharma Co. Ltd., Dublin, Ireland.
Coen M; Astellas Pharma Co. Ltd., Dublin, Ireland.
Garnham A; Astellas Pharma Europe Ltd, Chertsey, UK.
Watt M; Astellas Pharma Europe Ltd, Chertsey, UK.
Lacey L; Lacey Solutions Ltd., Dublin, Ireland.

J Health Econ Outcomes Res ; 2(2): 192-206, 2015.

Article em En | MEDLINE | ID: mdl-37663580

Palavras-chave

clostridium difficile infection; cost-utility analysis; fidaxomicin; macrocyclic antibiotic; recurrence

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: J Health Econ Outcomes Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google